At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2,366 enrolled
Drug / intervention
BMS-986177 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)
In Brief
A Phase 2 clinical trial evaluating BMS-986177, Placebo, and 2 other interventions for Acute Ischemic Stroke and Transient Ischemic Attack (TIA). Completed, enrolled 2,366 participants across 424 sites in 29 countries.
Detailed Summary
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Norway, Poland, Russia, South Korea, Spain, Sweden, Switzerland, United Kingdom, United States
CollaboratorsJanssen, LP
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJan 2019
Primary CompletionMar 2022
TodayJul 2026
First PostedDec 6, 2018
Enrollment StartJan 27, 2019
Primary CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.6 years ago
Interventions
BMS-986177drug
Oral administration
Placeboother
Oral Administration
Clopidogreldrug
Oral administration
Aspirindrug
Oral administration